224 related articles for article (PubMed ID: 9006785)
41. Dosage form-related food interaction observed in a marketed once-daily nifedipine formulation after a high-fat American breakfast.
Schug BS; Brendel E; Wonnemann M; Wolf D; Wargenau M; Dingler A; Blume HH
Eur J Clin Pharmacol; 2002 May; 58(2):119-25. PubMed ID: 12012144
[TBL] [Abstract][Full Text] [Related]
42. Influence of food on bioavailability from two controlled-release granules of theophylline.
Tada H; Ishikawa M; Sato E; Suzuki T; Unno K; Miura K; Ohmiya Y; Nakai K
J Clin Pharm Ther; 1989 Apr; 14(2):145-51. PubMed ID: 2722977
[TBL] [Abstract][Full Text] [Related]
43. [The effect of pretreatment with ranitidine on the pharmacokinetics and gastrointestinal transit of a sustained-release theophylline preparation].
Wilson CG; Washington N; Greaves JL; Blackshaw PE; Perkins AC; Barkworth MF; Rehm KD
Arzneimittelforschung; 1998 May; 48(5A):561-8. PubMed ID: 9676345
[TBL] [Abstract][Full Text] [Related]
44. Theophylline controlled-release formulations: in vivo-in vitro correlations.
Yu Z; Schwartz JB; Sugita ET
Biopharm Drug Dispos; 1996 Apr; 17(3):259-72. PubMed ID: 8983400
[TBL] [Abstract][Full Text] [Related]
45. Bioequivalence of a new sustained-release formulation of sodium valproate, valproate modified-release granules, compared with existing sustained-release formulations after once- or twice-daily administration.
Dulac O; Alvarez JC
Pharmacotherapy; 2005 Jan; 25(1):35-41. PubMed ID: 15767218
[TBL] [Abstract][Full Text] [Related]
46. Pharmacokinetics of a new sustained-release formulation of theophylline sodium glycerinate in healthy subjects with a new asymmetric dosage regimen.
Wang P; Qi M; Zhong D; Fang L
Biomed Chromatogr; 2003 Jan; 17(1):58-61. PubMed ID: 12583008
[TBL] [Abstract][Full Text] [Related]
47. Gallbladder motility in response to sham feeding and cholecystokinin in lean and obese subjects.
Masclee AA; Gielkens HA; Lieverse RJ; Penning C; Schipper J; Lamers CB
Digestion; 1997; 58(1):43-9. PubMed ID: 9018009
[TBL] [Abstract][Full Text] [Related]
48. Pharmacokinetic profile of a new sustained-release theophylline pellet formulation for once-daily evening administration.
Steinijans VW; Sauter R; Böhm A; Staudinger H
Arzneimittelforschung; 1988 Aug; 38(8A):1241-50. PubMed ID: 3190813
[TBL] [Abstract][Full Text] [Related]
49. In vitro and in vivo studies of a new sustained release formulation of morphine. Discrepancies between the in vitro release and the in vivo absorption in dogs.
Araícot A; Torres-Molina F; Saadeddin A; Cárcel-Trullols J; Alvarez-Fuentes J; Holgado A; Fernández-Arévalo M; Peris JE
Arzneimittelforschung; 2008; 58(12):647-52. PubMed ID: 19202736
[TBL] [Abstract][Full Text] [Related]
50. In vitro conditions for the study of the in vivo performance of sustained-release theophylline matrix tablets administered in fasted conditions and with a high-fat diet.
Andonaegui MT; Barría JL; Thielemann AM; Seitz C; Gai MN
Drug Dev Ind Pharm; 1999 Nov; 25(11):1199-203. PubMed ID: 10596358
[TBL] [Abstract][Full Text] [Related]
51. Gallbladder emptying and somatostatin and cholecystokinin plasma levels in celiac disease.
Fraquelli M; Bardella MT; Peracchi M; Cesana BM; Bianchi PA; Conte D
Am J Gastroenterol; 1999 Jul; 94(7):1866-70. PubMed ID: 10406250
[TBL] [Abstract][Full Text] [Related]
52. Activated charcoal alone and followed by whole-bowel irrigation in preventing the absorption of sustained-release drugs.
Lapatto-Reiniluoto O; Kivistö KT; Neuvonen PJ
Clin Pharmacol Ther; 2001 Sep; 70(3):255-60. PubMed ID: 11557913
[TBL] [Abstract][Full Text] [Related]
53. Oral sustained delivery of theophylline using in-situ gelation of sodium alginate.
Miyazaki S; Kubo W; Attwood D
J Control Release; 2000 Jul; 67(2-3):275-80. PubMed ID: 10825560
[TBL] [Abstract][Full Text] [Related]
54. [Role of food interaction pharmacokinetic studies in drug development. Food interaction studies of theophylline and nifedipine retard and buspirone tablets].
Drabant S; Klebovich I; Gachályi B; Renczes G; Farsang C
Acta Pharm Hung; 1998 Sep; 68(5):294-306. PubMed ID: 9805816
[TBL] [Abstract][Full Text] [Related]
55. [Revalidation of the in vitro specification limits after an in vitro-in vivo correlation].
Pabst G
Arzneimittelforschung; 1998 May; 48(5A):584-8. PubMed ID: 9676349
[TBL] [Abstract][Full Text] [Related]
56. [Comparative study of sustained-release in theophylline (Slobid, Theolong, Theodur) by pharmacokinetics].
Kotake T; Mihara M; Shibakawa M; Asamoto
Arerugi; 1997 Apr; 46(4):370-5. PubMed ID: 9154697
[TBL] [Abstract][Full Text] [Related]
57. Opposite effects of cholestyramine and loxiglumide on gallbladder dynamics in humans.
Palasciano G; Portincasa P; Belfiore A; Baldassarre G; Albano O
Gastroenterology; 1992 Feb; 102(2):633-9. PubMed ID: 1732132
[TBL] [Abstract][Full Text] [Related]
58. Assessment of the bioequivalence of two formulations of clarithromycin extended-release 500-mg tablets under fasting and fed conditions: a single-dose, randomized, open-label, two-period, two-way crossover study in healthy Jordanian male volunteers.
Alkhalidi BA; Tamimi JJ; Salem II; Ibrahim H; Sallam AA
Clin Ther; 2008 Oct; 30(10):1831-43. PubMed ID: 19014838
[TBL] [Abstract][Full Text] [Related]
59. The influence of food on the bioavailability of a slow release theophylline preparation.
Thebault JJ; Aiache JM; Mazoyer F; Cardot JM
Clin Pharmacokinet; 1987 Oct; 13(4):267-72. PubMed ID: 3665325
[TBL] [Abstract][Full Text] [Related]
60. [Comparative study of sustained-release in theophylline (Slobid, Theolong, Theodur) by pharmacokinetics].
Kotake T; Mihara M; Shibakawa M; Asamoto H
Nihon Rinsho; 1996 Nov; 54(11):3119-24. PubMed ID: 8950965
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
